You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameFosaprepitant
Accession NumberDB06717
TypeSmall Molecule
GroupsApproved
Description

Fosaprepitant is an intravenously administered antiemetic drug. It is a prodrug of Aprepitant. It aids in the prevention of acute and delayed nausea and vomiting associated with chemotherapy treatment.

Structure
Thumb
Synonyms
Fosaprepitantum
L-758,298
L-758298
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Emendinjection, powder, lyophilized, for solution115 mg/5mLintravenousMerck Sharp & Dohme Corp.2008-01-252016-02-18Us
Emendinjection, powder, lyophilized, for solution150 mg/5mLintravenousMerck Sharp & Dohme Corp.2008-01-25Not applicableUs
Emend IVpowder for solution115 mgintravenousMerck Canada Inc2009-04-302010-10-28Canada
Emend IVpowder for solution150 mgintravenousMerck Canada Inc2011-04-04Not applicableCanada
Fosaprepitantpowder for solution150 mgintravenousApotex IncNot applicableNot applicableCanada
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Fosaprepitant dimeglumine
265121-04-8
Thumb
  • InChI Key: VRQHBYGYXDWZDL-OOZCZQCLSA-N
  • Monoisotopic Mass: 1004.337863721
  • Average Mass: 1004.8337
DBSALT000089
Categories
UNII6L8OF9XRDC
CAS number172673-20-0
WeightAverage: 614.4066
Monoisotopic: 614.116518403
Chemical FormulaC23H22F7N4O6P
InChI KeyInChIKey=BARDROPHSZEBKC-OITMNORJSA-N
InChI
InChI=1S/C23H22F7N4O6P/c1-12(14-8-15(22(25,26)27)10-16(9-14)23(28,29)30)40-20-19(13-2-4-17(24)5-3-13)33(6-7-39-20)11-18-31-21(35)34(32-18)41(36,37)38/h2-5,8-10,12,19-20H,6-7,11H2,1H3,(H,31,32,35)(H2,36,37,38)/t12-,19+,20-/m1/s1
IUPAC Name
(3-{[(2R,3S)-2-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-3-(4-fluorophenyl)morpholin-4-yl]methyl}-5-oxo-2,5-dihydro-1H-1,2,4-triazol-1-yl)phosphonic acid
SMILES
C[C@@H](O[[email protected]]1OCCN(CC2=NC(=O)N(N2)P(O)(O)=O)[[email protected]]1C1=CC=C(F)C=C1)C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as phenylmorpholines. These are aromatic compounds containing a morpholine ring and a benzene ring linked to each other through a CC or a CN bond.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassOxazinanes
Sub ClassMorpholines
Direct ParentPhenylmorpholines
Alternative Parents
Substituents
  • Phenylmorpholine
  • Aralkylamine
  • Halobenzene
  • Fluorobenzene
  • Benzenoid
  • Monocyclic benzene moiety
  • Aryl halide
  • Aryl fluoride
  • Heteroaromatic compound
  • 1,2,4-triazole
  • Azole
  • Tertiary aliphatic amine
  • Tertiary amine
  • Oxacycle
  • Azacycle
  • Acetal
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Organofluoride
  • Organohalogen compound
  • Amine
  • Alkyl halide
  • Alkyl fluoride
  • Aromatic heteromonocyclic compound
Molecular FrameworkAromatic heteromonocyclic compounds
External Descriptors
Pharmacology
IndicationFor the prevention of nausea and vomiting associated with highly emetogenic cancer chemotherapy.
PharmacodynamicsFosaprepitant is a prodrug of Aprepitant. Once biologically activated, the drug acts as a substance P/neurokinin 1 (NK1) receptor antagonist which, in combination with other antiemetic agents, is indicated for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy. Aprepitant is a selective high-affinity antagonist of human substance P/neurokinin 1 (NK1) receptors. Aprepitant has little or no affinity for serotonin (5-HT3), dopamine, and corticosteroid receptors, the targets of existing therapies for chemotherapy-induced nausea and vomiting (CI NV).
Mechanism of actionAprepitant has been shown in animal models to inhibit emesis induced by cytotoxic chemotherapeutic agents, such as cisplatin, via central actions. Animal and human Positron Emission Tomography (PET) studies with Aprepitant have shown that it crosses the blood brain barrier and occupies brain NK1 receptors. Animal and human studies show that Aprepitant augments the antiemetic activity of the 5-HT3-receptor antagonist ondansetron and the corticosteroid ethasone and inhibits both the acute and delayed phases of cisplatin induced emesis. In summary, the active form of fosaprepitant is as an NK1 antagonist which is because it blocks signals given off by NK1 receptors. This therefore decreases the likelihood of vomiting in patients experiencing.
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein binding95% +
Metabolism

Aprepitant is metabolized primarily by CYP3A4 with minor metabolism by CYP1A2 and CYP2C19. Seven metabolites of aprepitant, which are only weakly active, have been identified in human plasma.

Route of eliminationAprepitant is eliminated primarily by metabolism; aprepitant is not renally excreted. Aprepitant is excreted in the milk of rats. It is not known whether this drug is excreted in human milk.
Half life9-13 hours
ClearanceNot Available
ToxicityNot Available
Affected organismsNot Available
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption-0.5225
Blood Brain Barrier-0.81
Caco-2 permeable-0.6534
P-glycoprotein substrateSubstrate0.8255
P-glycoprotein inhibitor INon-inhibitor0.6532
P-glycoprotein inhibitor IINon-inhibitor0.986
Renal organic cation transporterNon-inhibitor0.8583
CYP450 2C9 substrateNon-substrate0.7018
CYP450 2D6 substrateNon-substrate0.8588
CYP450 3A4 substrateSubstrate0.546
CYP450 1A2 substrateNon-inhibitor0.7539
CYP450 2C9 inhibitorNon-inhibitor0.644
CYP450 2D6 inhibitorNon-inhibitor0.8521
CYP450 2C19 inhibitorNon-inhibitor0.6705
CYP450 3A4 inhibitorInhibitor0.6258
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.5
Ames testNon AMES toxic0.5349
CarcinogenicityNon-carcinogens0.7701
BiodegradationNot ready biodegradable0.9899
Rat acute toxicity2.6064 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.5
hERG inhibition (predictor II)Inhibitor0.6528
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage forms
FormRouteStrength
Injection, powder, lyophilized, for solutionintravenous115 mg/5mL
Injection, powder, lyophilized, for solutionintravenous150 mg/5mL
Powder for solutionintravenous115 mg
Powder for solutionintravenous150 mg
PricesNot Available
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US5691336 No1999-03-042019-03-04Us
Properties
StateSolid
Experimental PropertiesNot Available
Predicted Properties
PropertyValueSource
Water Solubility0.00632 mg/mLALOGPS
logP2.89ALOGPS
logP2.4ChemAxon
logS-5ALOGPS
pKa (Strongest Acidic)1.02ChemAxon
pKa (Strongest Basic)5.69ChemAxon
Physiological Charge-2ChemAxon
Hydrogen Acceptor Count9ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area123.93 Å2ChemAxon
Rotatable Bond Count9ChemAxon
Refractivity138.63 m3·mol-1ChemAxon
Polarizability49.92 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
SpectraNot Available
References
Synthesis Reference

Navin Ganesh Bhatt, Nikhil Rasiklal Trivedi, Mahesh Khedekar, Sukumar Sinha, Mubeen Ahmed Khan, Ramjilal Yadav, “FOSAPREPITANT DIMEGLUMINE INTERMEDIATE, NEUTRAL FOSAPREPITANT, AND AMORPHOUS FOSAPREPITANT DIMEGLUMINE AND PROCESSES FOR THEIR PREPARATIONS.” U.S. Patent US20110130366, issued June 02, 2011.

US20110130366
General ReferencesNot Available
External Links
ATC CodesNot Available
AHFS Codes
  • 56:22.92
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
Interactions
Drug Interactions
Drug
AlfentanilThe serum concentration of Alfentanil can be increased when it is combined with Fosaprepitant.
AlfuzosinThe serum concentration of Alfuzosin can be increased when it is combined with Fosaprepitant.
AlitretinoinThe serum concentration of Alitretinoin can be increased when it is combined with Fosaprepitant.
AlprazolamThe serum concentration of Alprazolam can be increased when it is combined with Fosaprepitant.
AminophyllineThe serum concentration of Aminophylline can be increased when it is combined with Fosaprepitant.
AmiodaroneThe serum concentration of Amiodarone can be increased when it is combined with Fosaprepitant.
AmlodipineThe serum concentration of Amlodipine can be increased when it is combined with Fosaprepitant.
AprepitantThe serum concentration of Aprepitant can be increased when it is combined with FosAprepitant.
AripiprazoleThe serum concentration of Aripiprazole can be decreased when it is combined with Fosaprepitant.
ArmodafinilThe serum concentration of Armodafinil can be increased when it is combined with Fosaprepitant.
AstemizoleThe serum concentration of Astemizole can be increased when it is combined with Fosaprepitant.
AtorvastatinThe serum concentration of Atorvastatin can be increased when it is combined with Fosaprepitant.
AvanafilThe serum concentration of Avanafil can be increased when it is combined with Fosaprepitant.
AxitinibThe serum concentration of Axitinib can be increased when it is combined with Fosaprepitant.
BenzphetamineThe serum concentration of Benzphetamine can be increased when it is combined with Fosaprepitant.
BetamethasoneThe serum concentration of Betamethasone can be increased when it is combined with Fosaprepitant.
BexaroteneThe serum concentration of Fosaprepitant can be decreased when it is combined with Bexarotene.
BisoprololThe serum concentration of Bisoprolol can be increased when it is combined with Fosaprepitant.
BosentanThe serum concentration of Fosaprepitant can be decreased when it is combined with Bosentan.
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Fosaprepitant.
BrexpiprazoleThe serum concentration of Brexpiprazole can be increased when it is combined with Fosaprepitant.
BromocriptineThe serum concentration of Bromocriptine can be increased when it is combined with Fosaprepitant.
BudesonideThe serum concentration of Budesonide can be increased when it is combined with Fosaprepitant.
BuprenorphineThe serum concentration of Buprenorphine can be increased when it is combined with Fosaprepitant.
BuspironeThe serum concentration of Buspirone can be increased when it is combined with Fosaprepitant.
CabazitaxelThe serum concentration of Cabazitaxel can be increased when it is combined with Fosaprepitant.
CabozantinibThe serum concentration of Cabozantinib can be increased when it is combined with Fosaprepitant.
CalcitriolThe serum concentration of Calcitriol can be increased when it is combined with Fosaprepitant.
ChlordiazepoxideThe serum concentration of Chlordiazepoxide can be increased when it is combined with Fosaprepitant.
ChloroquineThe serum concentration of Chloroquine can be increased when it is combined with Fosaprepitant.
ChlorotrianiseneThe serum concentration of Chlorotrianisene can be decreased when it is combined with Fosaprepitant.
CilostazolThe serum concentration of Cilostazol can be increased when it is combined with Fosaprepitant.
CinacalcetThe serum concentration of Cinacalcet can be increased when it is combined with Fosaprepitant.
CisaprideThe serum concentration of Cisapride can be increased when it is combined with Fosaprepitant.
CitalopramThe serum concentration of Citalopram can be increased when it is combined with Fosaprepitant.
ClonazepamThe serum concentration of Clonazepam can be increased when it is combined with Fosaprepitant.
ClorazepateThe serum concentration of Clorazepate can be increased when it is combined with Fosaprepitant.
CobimetinibThe serum concentration of Cobimetinib can be increased when it is combined with Fosaprepitant.
CocaineThe serum concentration of Cocaine can be increased when it is combined with Fosaprepitant.
ColchicineThe serum concentration of Colchicine can be increased when it is combined with Fosaprepitant.
ConivaptanThe serum concentration of Fosaprepitant can be increased when it is combined with Conivaptan.
CorticotropinThe serum concentration of Corticotropin can be increased when it is combined with Fosaprepitant.
Cortisone acetateThe serum concentration of Cortisone acetate can be increased when it is combined with Fosaprepitant.
CrizotinibThe serum concentration of Crizotinib can be increased when it is combined with Fosaprepitant.
CyclosporineThe serum concentration of Cyclosporine can be increased when it is combined with Fosaprepitant.
Cyproterone acetateThe serum concentration of Cyproterone acetate can be increased when it is combined with Fosaprepitant.
DabrafenibThe serum concentration of Fosaprepitant can be decreased when it is combined with Dabrafenib.
DaclatasvirThe serum concentration of Daclatasvir can be increased when it is combined with Fosaprepitant.
DantroleneThe serum concentration of Dantrolene can be increased when it is combined with Fosaprepitant.
DapsoneThe serum concentration of Dapsone can be increased when it is combined with Fosaprepitant.
DarifenacinThe serum concentration of Darifenacin can be increased when it is combined with Fosaprepitant.
DasatinibThe serum concentration of Dasatinib can be increased when it is combined with Fosaprepitant.
DeferasiroxThe serum concentration of Fosaprepitant can be decreased when it is combined with Deferasirox.
DexamethasoneThe serum concentration of Dexamethasone can be increased when it is combined with Fosaprepitant.
DiazepamThe serum concentration of Diazepam can be increased when it is combined with Fosaprepitant.
DienogestThe serum concentration of Dienogest can be decreased when it is combined with Fosaprepitant.
DihydroergotamineThe serum concentration of Dihydroergotamine can be increased when it is combined with Fosaprepitant.
DiltiazemThe serum concentration of Diltiazem can be increased when it is combined with Fosaprepitant.
DisopyramideThe serum concentration of Disopyramide can be increased when it is combined with Fosaprepitant.
DofetilideThe serum concentration of Dofetilide can be increased when it is combined with Fosaprepitant.
DomperidoneThe serum concentration of Domperidone can be increased when it is combined with Fosaprepitant.
DoxazosinThe serum concentration of Doxazosin can be increased when it is combined with Fosaprepitant.
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Fosaprepitant.
DronedaroneThe serum concentration of Dronedarone can be increased when it is combined with Fosaprepitant.
EletriptanThe serum concentration of Eletriptan can be increased when it is combined with Fosaprepitant.
EliglustatThe serum concentration of Eliglustat can be increased when it is combined with Fosaprepitant.
EplerenoneThe serum concentration of Eplerenone can be increased when it is combined with Fosaprepitant.
Ergoloid mesylateThe serum concentration of Ergoloid mesylate can be increased when it is combined with Fosaprepitant.
ErgonovineThe serum concentration of Ergonovine can be increased when it is combined with Fosaprepitant.
ErgotamineThe serum concentration of Ergotamine can be increased when it is combined with Fosaprepitant.
ErlotinibThe serum concentration of Erlotinib can be increased when it is combined with Fosaprepitant.
ErythromycinThe serum concentration of Erythromycin can be increased when it is combined with Fosaprepitant.
EscitalopramThe serum concentration of Escitalopram can be increased when it is combined with Fosaprepitant.
EszopicloneThe serum concentration of Eszopiclone can be increased when it is combined with Fosaprepitant.
EthosuximideThe serum concentration of Ethosuximide can be increased when it is combined with Fosaprepitant.
EtonogestrelThe serum concentration of Etonogestrel can be decreased when it is combined with Fosaprepitant.
EtoposideThe serum concentration of Etoposide can be increased when it is combined with Fosaprepitant.
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Fosaprepitant.
FelbamateThe serum concentration of Felbamate can be increased when it is combined with Fosaprepitant.
FelodipineThe serum concentration of Felodipine can be increased when it is combined with Fosaprepitant.
FentanylThe serum concentration of Fentanyl can be increased when it is combined with Fosaprepitant.
FesoterodineThe serum concentration of Fesoterodine can be increased when it is combined with Fosaprepitant.
FlibanserinThe serum concentration of Flibanserin can be increased when it is combined with Fosaprepitant.
FluconazoleThe metabolism of Fosaprepitant can be decreased when combined with Fluconazole.
FludrocortisoneThe serum concentration of Fludrocortisone can be increased when it is combined with Fosaprepitant.
FlunisolideThe serum concentration of Flunisolide can be increased when it is combined with Fosaprepitant.
FlurazepamThe serum concentration of Flurazepam can be increased when it is combined with Fosaprepitant.
FlutamideThe serum concentration of Flutamide can be increased when it is combined with Fosaprepitant.
Fusidic AcidThe serum concentration of Fosaprepitant can be increased when it is combined with Fusidic Acid.
GefitinibThe serum concentration of Gefitinib can be increased when it is combined with Fosaprepitant.
GuanfacineThe serum concentration of Guanfacine can be increased when it is combined with Fosaprepitant.
HaloperidolThe serum concentration of Haloperidol can be increased when it is combined with Fosaprepitant.
HydrocodoneThe serum concentration of Hydrocodone can be increased when it is combined with Fosaprepitant.
HydrocortisoneThe serum concentration of Hydrocortisone can be increased when it is combined with Fosaprepitant.
Hydroxyprogesterone caproateThe serum concentration of Hydroxyprogesterone caproate can be increased when it is combined with Fosaprepitant.
IbrutinibThe serum concentration of Ibrutinib can be increased when it is combined with Fosaprepitant.
IdelalisibThe serum concentration of Fosaprepitant can be increased when it is combined with Idelalisib.
IfosfamideThe serum concentration of Ifosfamide can be increased when it is combined with Fosaprepitant.
IrinotecanThe serum concentration of Irinotecan can be increased when it is combined with Fosaprepitant.
IsavuconazoniumThe serum concentration of Isavuconazonium can be increased when it is combined with Fosaprepitant.
IsosorbideThe serum concentration of Isosorbide can be increased when it is combined with Fosaprepitant.
Isosorbide DinitrateThe serum concentration of Isosorbide Dinitrate can be increased when it is combined with Fosaprepitant.
Isosorbide MononitrateThe serum concentration of Isosorbide Mononitrate can be increased when it is combined with Fosaprepitant.
IsradipineThe serum concentration of Isradipine can be increased when it is combined with Fosaprepitant.
IvabradineThe serum concentration of Ivabradine can be increased when it is combined with Fosaprepitant.
IvacaftorThe serum concentration of Fosaprepitant can be increased when it is combined with Ivacaftor.
IxabepiloneThe serum concentration of Ixabepilone can be increased when it is combined with Fosaprepitant.
KetamineThe serum concentration of Ketamine can be increased when it is combined with Fosaprepitant.
LapatinibThe serum concentration of Lapatinib can be increased when it is combined with Fosaprepitant.
LevomilnacipranThe serum concentration of Levomilnacipran can be increased when it is combined with Fosaprepitant.
LevonorgestrelThe serum concentration of Levonorgestrel can be decreased when it is combined with Fosaprepitant.
LidocaineThe serum concentration of Lidocaine can be increased when it is combined with Fosaprepitant.
LomitapideThe serum concentration of Lomitapide can be increased when it is combined with Fosaprepitant.
LovastatinThe serum concentration of Lovastatin can be increased when it is combined with Fosaprepitant.
LuliconazoleThe serum concentration of Fosaprepitant can be increased when it is combined with Luliconazole.
LurasidoneThe serum concentration of Lurasidone can be increased when it is combined with Fosaprepitant.
MacitentanThe serum concentration of MACITENTAN can be increased when it is combined with Fosaprepitant.
MaravirocThe serum concentration of Maraviroc can be increased when it is combined with Fosaprepitant.
Medroxyprogesterone acetateThe serum concentration of Medroxyprogesterone Acetate can be decreased when it is combined with Fosaprepitant.
MefloquineThe serum concentration of Mefloquine can be increased when it is combined with Fosaprepitant.
MethadoneThe serum concentration of Methadone can be increased when it is combined with Fosaprepitant.
MethylprednisoloneThe serum concentration of Methylprednisolone can be increased when it is combined with Fosaprepitant.
MidazolamThe serum concentration of Midazolam can be increased when it is combined with Fosaprepitant.
MifepristoneThe serum concentration of Fosaprepitant can be increased when it is combined with Mifepristone.
MirtazapineThe serum concentration of Mirtazapine can be increased when it is combined with Fosaprepitant.
MitotaneThe serum concentration of Fosaprepitant can be decreased when it is combined with Mitotane.
ModafinilThe serum concentration of Modafinil can be increased when it is combined with Fosaprepitant.
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Fosaprepitant.
NateglinideThe serum concentration of Nateglinide can be increased when it is combined with Fosaprepitant.
NelfinavirThe metabolism of Fosaprepitant can be decreased when combined with Nelfinavir.
NetupitantThe serum concentration of Fosaprepitant can be increased when it is combined with Netupitant.
NicardipineThe serum concentration of Nicardipine can be increased when it is combined with Fosaprepitant.
NifedipineThe serum concentration of Nifedipine can be increased when it is combined with Fosaprepitant.
NilotinibThe serum concentration of Nilotinib can be increased when it is combined with Fosaprepitant.
NimodipineThe serum concentration of Nimodipine can be increased when it is combined with Fosaprepitant.
NisoldipineThe serum concentration of Nisoldipine can be increased when it is combined with Fosaprepitant.
NorethisteroneThe serum concentration of Norethindrone can be decreased when it is combined with Fosaprepitant.
OlaparibThe serum concentration of Olaparib can be increased when it is combined with Fosaprepitant.
OxycodoneThe serum concentration of Oxycodone can be increased when it is combined with Fosaprepitant.
PaclitaxelThe serum concentration of Paclitaxel can be increased when it is combined with Fosaprepitant.
PalbociclibThe serum concentration of Fosaprepitant can be increased when it is combined with Palbociclib.
PanobinostatThe serum concentration of Panobinostat can be increased when it is combined with Fosaprepitant.
ParoxetineThe serum concentration of the active metabolites of Fosaprepitant can be reduced when Fosaprepitant is used in combination with Paroxetine resulting in a loss in efficacy.
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Fosaprepitant.
PhenytoinThe metabolism of Fosaprepitant can be increased when combined with Phenytoin.
PimozideThe serum concentration of Pimozide can be increased when it is combined with Fosaprepitant.
PipotiazineThe serum concentration of Pipotiazine can be increased when it is combined with Fosaprepitant.
PraziquantelThe serum concentration of Praziquantel can be increased when it is combined with Fosaprepitant.
PrednisoloneThe serum concentration of Prednisolone can be increased when it is combined with Fosaprepitant.
PrednisoneThe serum concentration of Prednisone can be increased when it is combined with Fosaprepitant.
QuetiapineThe serum concentration of Quetiapine can be increased when it is combined with Fosaprepitant.
QuinidineThe serum concentration of Quinidine can be increased when it is combined with Fosaprepitant.
QuinineThe serum concentration of Quinine can be increased when it is combined with Fosaprepitant.
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Fosaprepitant.
RegorafenibThe serum concentration of Regorafenib can be increased when it is combined with Fosaprepitant.
Repository corticotropinThe serum concentration of Repository corticotropin can be increased when it is combined with Fosaprepitant.
RifampicinThe serum concentration of Fosaprepitant can be decreased when it is combined with Rifampicin.
RuxolitinibThe serum concentration of Ruxolitinib can be increased when it is combined with Fosaprepitant.
SalmeterolThe serum concentration of Salmeterol can be increased when it is combined with Fosaprepitant.
SaxagliptinThe serum concentration of Saxagliptin can be increased when it is combined with Fosaprepitant.
SildenafilThe serum concentration of Sildenafil can be increased when it is combined with Fosaprepitant.
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Fosaprepitant.
SiltuximabThe serum concentration of Fosaprepitant can be decreased when it is combined with Siltuximab.
SimeprevirThe serum concentration of Simeprevir can be increased when it is combined with Fosaprepitant.
SimvastatinThe serum concentration of Simvastatin can be increased when it is combined with Fosaprepitant.
SirolimusThe serum concentration of Sirolimus can be increased when it is combined with Fosaprepitant.
SolifenacinThe serum concentration of Solifenacin can be increased when it is combined with Fosaprepitant.
SonidegibThe serum concentration of Sonidegib can be increased when it is combined with Fosaprepitant.
SpiramycinThe serum concentration of Spiramycin can be increased when it is combined with Fosaprepitant.
St. John's WortThe serum concentration of Fosaprepitant can be decreased when it is combined with St. John's Wort.
StiripentolThe serum concentration of Fosaprepitant can be increased when it is combined with Stiripentol.
SufentanilThe serum concentration of Sufentanil can be increased when it is combined with Fosaprepitant.
SunitinibThe serum concentration of Sunitinib can be increased when it is combined with Fosaprepitant.
SuvorexantThe serum concentration of Suvorexant can be increased when it is combined with Fosaprepitant.
TacrolimusThe serum concentration of Tacrolimus can be increased when it is combined with Fosaprepitant.
TadalafilThe serum concentration of Tadalafil can be increased when it is combined with Fosaprepitant.
TamoxifenThe serum concentration of Tamoxifen can be increased when it is combined with Fosaprepitant.
TamsulosinThe serum concentration of Tamsulosin can be increased when it is combined with Fosaprepitant.
TemsirolimusThe serum concentration of Temsirolimus can be increased when it is combined with Fosaprepitant.
TeniposideThe serum concentration of Teniposide can be increased when it is combined with Fosaprepitant.
TerfenadineThe serum concentration of Terfenadine can be increased when it is combined with Fosaprepitant.
TheophyllineThe serum concentration of Theophylline can be increased when it is combined with Fosaprepitant.
TiagabineThe serum concentration of Tiagabine can be increased when it is combined with Fosaprepitant.
TocilizumabThe serum concentration of Fosaprepitant can be decreased when it is combined with Tocilizumab.
TofacitinibThe serum concentration of Tofacitinib can be increased when it is combined with Fosaprepitant.
TolbutamideThe serum concentration of Tolbutamide can be decreased when it is combined with Fosaprepitant.
TolterodineThe serum concentration of Tolterodine can be increased when it is combined with Fosaprepitant.
TolvaptanThe serum concentration of Tolvaptan can be increased when it is combined with Fosaprepitant.
TrabectedinThe serum concentration of Trabectedin can be increased when it is combined with Fosaprepitant.
Trastuzumab emtansineThe serum concentration of ado-trastuzumab emtansine can be increased when it is combined with Fosaprepitant.
TrazodoneThe serum concentration of Trazodone can be increased when it is combined with Fosaprepitant.
TriamcinoloneThe serum concentration of Triamcinolone can be increased when it is combined with Fosaprepitant.
TriazolamThe serum concentration of Triazolam can be increased when it is combined with Fosaprepitant.
TrimipramineThe serum concentration of Trimipramine can be increased when it is combined with Fosaprepitant.
VardenafilThe serum concentration of Vardenafil can be increased when it is combined with Fosaprepitant.
VemurafenibThe serum concentration of Vemurafenib can be increased when it is combined with Fosaprepitant.
VenlafaxineThe serum concentration of Venlafaxine can be increased when it is combined with Fosaprepitant.
VerapamilThe serum concentration of Verapamil can be increased when it is combined with Fosaprepitant.
VinblastineThe serum concentration of Vinblastine can be increased when it is combined with Fosaprepitant.
VincristineThe serum concentration of Vincristine can be increased when it is combined with Fosaprepitant.
VinorelbineThe serum concentration of Vinorelbine can be increased when it is combined with Fosaprepitant.
WarfarinThe serum concentration of Warfarin can be decreased when it is combined with Fosaprepitant.
ZolpidemThe serum concentration of Zolpidem can be increased when it is combined with Fosaprepitant.
ZonisamideThe serum concentration of Zonisamide can be increased when it is combined with Fosaprepitant.
ZopicloneThe serum concentration of Zopiclone can be increased when it is combined with Fosaprepitant.
Food InteractionsNot Available
Comments
comments powered by Disqus
Drug created on May 16, 2010 18:16 / Updated on July 29, 2016 01:51